No Data
No Data
6 Analysts Assess Chemours: What You Need To Know
Chemours Outlines 2025 Adjusted EBITDA Guidance at $825M-$950M Amid Opteon Growth and Cost Reductions
Express News | Chemours Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results. Also, UBS Lowered Its Price Target on the Stock From $18 to $17
Chemours Is Maintained at Buy by UBS
Chemours Analyst Ratings
Express News | Chemours : Mizuho Cuts Target Price to $13 From $15